Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma

Neelapu, 2017, Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma, N Engl J Med, 377, 2531, 10.1056/NEJMoa1707447

Maude, 2014, Chimeric antigen receptor T cells for sustained remissions in leukemia, N Engl J Med, 371, 1507, 10.1056/NEJMoa1407222

Raje, 2019, Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma, N Engl J Med, 380, 1726, 10.1056/NEJMoa1817226

Sadelain, 2013, The basic principles of chimeric antigen receptor design, Cancer Discov, 3, 388, 10.1158/2159-8290.CD-12-0548

Ogba, 2018, Chimeric antigen receptor T-cell therapy, J Natl Compr Cancer Netw, 16, 1092, 10.6004/jnccn.2018.0073

Ramos, 2011, Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy, Expert Opin Biol Ther, 11, 855, 10.1517/14712598.2011.573476

Grupp, 2013, Chimeric antigen receptor–modified T cells for acute lymphoid leukemia, N Engl J Med, 368, 1509, 10.1056/NEJMoa1215134

Maude, 2018, Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia, N Engl J Med, 378, 439, 10.1056/NEJMoa1709866

Schuster, 2017, Chimeric antigen receptor T cells in refractory B-cell lymphomas, N Engl J Med, 377, 2545, 10.1056/NEJMoa1708566

Schuster, 2019, Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma, N Engl J Med, 380, 45, 10.1056/NEJMoa1804980

Porter, 2011, Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia, N Engl J Med, 365, 725, 10.1056/NEJMoa1103849

Carpenter, 2013, B-Cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma, Clin Cancer Res, 19, 2048, 10.1158/1078-0432.CCR-12-2422

Ellebrecht, 2016, Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease, Science, 353, 179, 10.1126/science.aaf6756

Samaha, 2018, A homing system targets therapeutic T cells to brain cancer, Nature, 561, 331, 10.1038/s41586-018-0499-y

D’Aloia, 2018, CAR-T cells: the long and winding road to solid tumors review-article, Cell Death Dis, 9, 282, 10.1038/s41419-018-0278-6

Turtle, 2016, CD19 CAR-T cells of defined CD4+:CD8+composition in adult B cell ALL patients, J Clin Invest, 126, 2123, 10.1172/JCI85309

Schuster, 2017, Primary analysis of Juliet: a global, pivotal, phase 2 trial of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma, Blood, 130, 577

2017, FDA Briefing Document Oncologic Drugs Advisory Committee Meeting - BLA 125646 Tisagenlecleucel Novartis Pharmaceuticals Corporation, FDA

Jhaveri, 2018, Chimeric antigen receptor T cell therapy and the kidney, Clin J Am Soc Nephrol, 13, 796, 10.2215/CJN.12871117

Dixon, 2017, Risk of hyponatremia and associated clinical characteristics in patients with acute lymphoblastic leukemia after CD19 targeted chimeric antigen receptor (CAR) T-cells, Blood, 130, 3584

Fitzgerald, 2017, Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia, Crit Care Med, 45, e124, 10.1097/CCM.0000000000002053

Turtle, 2015, Addition of fludarabine to cyclophosphamide lymphodepletion improves in vivo expansion of CD19 chimeric antigen receptor-modified T cells and clinical outcome in adults with B cell acute lymphoblastic leukemia, Blood, 126, 3773, 10.1182/blood.V126.23.3773.3773

Brentjens, 2011, Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias, Blood, 118, 4817, 10.1182/blood-2011-04-348540

Levey, 2010, Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions, Am J Kidney Dis, 55, 622, 10.1053/j.ajkd.2010.02.337

US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE. Bethesda, MD: National Institutes of Health, National Cancer Institute; 2017.

Lee, 2014, Current concepts in the diagnosis and management of cytokine release syndrome, Blood, 124, 188, 10.1182/blood-2014-05-552729

Neelapu, 2018, Chimeric antigen receptor T-cell therapy-assessment and management of toxicities, Nat Rev Clin Oncol, 15, 47, 10.1038/nrclinonc.2017.148

Teachey, 2016, Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia, Cancer Discov, 6, 664, 10.1158/2159-8290.CD-16-0040

Jayachandran, 2009, Cyclophosphamide-associated complications: we need to be aware of SIADH and central pontine myelinolysis, Rheumatology, 48, 89, 10.1093/rheumatology/ken402

Bruining, 2011, Cyclophosphamide-induced symptomatic hyponatraemia, Neth J Med, 69, 192

Durlacher-Betzer, 2018, Interleukin-6 contributes to the increase in fibroblast growth factor 23 expression in acute and chronic kidney disease, Kidney Int, 94, 315, 10.1016/j.kint.2018.02.026